The Motley Fool

GlaxoSmithKline’s share price is rising. Is it time to buy?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Businessman leading a chart upwards
Image source: Getty Images.

GlaxoSmithKline (LSE: GSK) shares have not had the best run over the last year. Trading above 1,700p in late June, the share price fell below 1,250p in early February. However, in the last two weeks or so, sentiment towards the FTSE 100 company looks to have improved dramatically, with the shares suddenly bouncing over 10%. While the stock is still 18% off its 52-week high, over the last month, it has outperformed the FTSE All Share index by 8%. So what has happened that has impacted sentiment towards Glaxo, and is now the time to buy?

Dividend concerns

Over the last year, many investors have been concerned about a potential acquisition of Pfizer’s consumer healthcare unit. An acquisition of this size would have put pressure on GlaxoSmithKline’s ability to maintain its dividend. When quizzed on the prospects for the dividend late last year, GSK CEO Emma Walmsley was reluctant to give much away, doing little to ease investors’ nerves. With dividend cover looking thin in recent years, it’s not surprising that some investors have moved away from Glaxo in the pursuit of more sustainable dividends.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Novartis deal

However, on 23 March, Glaxo announced that it had withdrawn its interest in Pfizer’s consumer healthcare business, with Walmsley stating that any potential deals must not compromise the group’s priorities for capital allocation. Then, just four days later, GSK announced that it had reached an agreement with Novartis for the buyout of its 36.5% stake in their consumer healthcare joint venture for $13bn.

The market was happy with this news. The transaction is expected to make a positive contribution to adjusted earnings this year and thereafter, strengthen operational cash flows, and boost operating margins to ‘mid-20s’ by 2022. Walmsley commented: “For the Group, the transaction is expected to benefit adjusted earnings and cash flows, helping us accelerate efforts to improve performance. Most importantly it also removes uncertainty and allows us to plan use of our capital for other priorities, especially pharmaceuticals R&D.”

Is now the time to buy?

With the uncertainty over a potential Pfizer deal removed, the investment case for GlaxoSmithKline certainty looks a lot more interesting, in my view. The new deal appears to make sense for the company, even if the extra debt associated with the acquisition does add an element of risk. The company has advised that it will launch a strategic review of its consumer nutrition products, including Horlicks, to support the funding of the transaction.

With earnings predicted to hit 106.8p per share this year, Glaxo currently trades on a forward-looking P/E ratio of 13.3. This is below the FTSE 100 average forward P/E of 14. Furthermore, as my colleague Rupert Hargreaves noted at the weekend, GSK’s valuation is significantly below that of US peers such as Johnson & Johnson, Merck & Co Inc, Bristol-Myers Squibb Co and Eli Lilly and Co, which together trade at an average forward P/E of 15.7.

GSK’s dividend yield also looks attractive at present, even if no growth is to be expected in the short term. The company advised in February that shareholders can continue to expect a payout of 80p per share this year, which equates to a yield of 5.6% at the current share price.

Weighing up these factors and with the Pfizer uncertainty removed, I believe that now could be a good time to take a closer look at the stock.

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic…

And with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be daunting prospect during such unprecedented times.

Fortunately, The Motley Fool is here to help: our UK Chief Investment Officer and his analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global lock-down…

You see, here at The Motley Fool we don’t believe “over-trading” is the right path to financial freedom in retirement; instead, we advocate buying and holding (for AT LEAST three to five years) 15 or more quality companies, with shareholder-focused management teams at the helm.

That’s why we’re sharing the names of all five of these companies in a special investing report that you can download today for FREE. If you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio, and that you can consider building a position in all five right away.

Click here to claim your free copy of this special investing report now!

Edward Sheldon owns shares in GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.